Argentina vs Morocco: Average cost of drugs for extensively drug-resistant tuberculosis
Argentina
4,721 constant 2022 US$
in 2024
Morocco
4,500 constant 2022 US$
in 2024
Argentina rank
12th
Morocco rank
14th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Argentina
- Morocco
How they compare
Argentina currently reports 4,721 constant 2022 US$ against 4,500 constant 2022 US$ in Morocco, a difference of 221 constant 2022 US$.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Argentina ahead.
Argentina ranks 12th and Morocco ranks 14th of 56 countries.
Across the 2 decades both report, Argentina averaged higher in 1 and Morocco in 1.
Head to head by decade
| Decade | Argentina | Morocco | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 9,142 constant 2022 US$ | 7,423 constant 2022 US$ | 1,719 constant 2022 US$ | Argentina |
| 2020s | 2,508 constant 2022 US$ | 3,909 constant 2022 US$ | 1,401 constant 2022 US$ | Morocco |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Argentina or Morocco?
- Argentina, at 4,721 constant 2022 US$ against 4,500 constant 2022 US$ in Morocco as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Argentina and Morocco?
- 221 constant 2022 US$, with Argentina ahead.
- How many years of comparable data are there for Argentina and Morocco?
- 8 years are reported by both, from 2017 to 2024.
- How do Argentina and Morocco rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Argentina ranks 12th and Morocco ranks 14th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.